Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Fast Track Articles
  5. Fast Track Article
image of Safety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study

Abstract

Background

Anlotinib has demonstrated durable clinical benefits in patients with unresectable or metastatic bone and soft-tissue sarcomas.

Methods

92 patients treated with chemotherapy combined with or without anlotinib were collected and analyzed. The objective response rate (ORR) and disease control rate (DCR) were analyzed. Long-term survival was assessed using the Kaplan-Meier method, including median progression-free survival (mPFS) and overall survival (mOS).

Results

Liposarcoma, synovial sarcoma, and rhabdomyosarcoma were the primary pathological subtypes of the 92 patients. The median age was 46 (range, 11–75) years. The ORR and DCR of the anlotinib-chemotherapy combination used as first-line therapy were 31.9% and 85.1%, respectively. However, the ORR and DCR were only 6.7% and 57.8% in the chemotherapy alone, respectively. Compared with the chemotherapy group, improvements were observed in the mPFS and mOS with anlotinib-based regimen (mPFS, 8.3 vs. 3.0 months; mOS, 59.0 vs. 22.0 months). Anlotinib-associated adverse events were well tolerated and mainly occurred in grades I and II. New anlotinib-related adverse reactions were not noted.

Conclusion

Anlotinib-based regimen as a first-line therapy showed a positive effect on the treatment of unresectable or metastatic BSTSs. The anlotinib-associated adverse events were minor and well tolerated.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206336884241216070930
2025-01-16
2025-03-29

  • From This Site

    /content/journals/acamc/10.2174/0118715206336884241216070930
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Sbaraglia M. Bellan E. Dei Tos A.P. The 2020 who classification of soft tissue tumours: News and perspectives. Pathologica 2020 113 2 70 84 10.32074/1591‑951X‑213 33179614
    [Google Scholar]
  2. Chi Y. Fang Z. Hong X. Yao Y. Sun P. Wang G. Du F. Sun Y. Wu Q. Qu G. Wang S. Song J. Yu J. Lu Y. Zhu X. Niu X. He Z. Wang J. Yu H. Cai J. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin. Cancer Res. 2018 24 21 5233 5238 10.1158/1078‑0432.CCR‑17‑3766 29895706
    [Google Scholar]
  3. Yang Z. Zheng R. Zhang S. Zeng H. Li H. Chen W. Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol. Med. 2019 16 3 565 574 10.20892/j.issn.2095‑3941.2019.0041 31565485
    [Google Scholar]
  4. Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2018. CA Cancer J. Clin. 2018 68 1 7 30 10.3322/caac.21442 29313949
    [Google Scholar]
  5. Whelan J.S. Davis L.E. Osteosarcoma, chondrosarcoma, and chordoma. J. Clin. Oncol. 2018 36 2 188 193 10.1200/JCO.2017.75.1743 29220289
    [Google Scholar]
  6. Riggi N. Suvà M.L. Stamenkovic I. Ewing’s sarcoma. reply. N. Engl. J. Med. 2021 384 15 1477 1478 33852794
    [Google Scholar]
  7. Singhi E. Moore D. Muslimani A. Metastatic soft tissue sarcomas: A review of treatment and new pharmacotherapies. P T 2018 43 7 410 429 30013298
    [Google Scholar]
  8. Smrke A. Wang Y. Simmons C. Update on systemic therapy for advanced soft-tissue sarcoma. Curr. Oncol. 2020 27 11 Suppl. 1 25 33 10.3747/co.27.5475 32174755
    [Google Scholar]
  9. Savina M. Le Cesne A. Blay J.Y. Ray-Coquard I. Mir O. Toulmonde M. Cousin S. Terrier P. Ranchere-Vince D. Meeus P. Stoeckle E. Honoré C. Sargos P. Sunyach M.P. Le Péchoux C. Giraud A. Bellera C. Le Loarer F. Italiano A. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: The METASARC observational study. BMC Med. 2017 15 1 78 10.1186/s12916‑017‑0831‑7 28391775
    [Google Scholar]
  10. Reed D.R. Hayashi M. Wagner L. Binitie O. Steppan D.A. Brohl A.S. Shinohara E.T. Bridge J.A. Loeb D.M. Borinstein S.C. Isakoff M.S. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer 2017 123 12 2206 2218 10.1002/cncr.30589 28323337
    [Google Scholar]
  11. Judson I. Verweij J. Gelderblom H. Hartmann J.T. Schöffski P. Blay J.Y. Kerst J.M. Sufliarsky J. Whelan J. Hohenberger P. Krarup-Hansen A. Alcindor T. Marreaud S. Litière S. Hermans C. Fisher C. Hogendoorn P.C.W. dei Tos A.P. van der Graaf W.T.A. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial. Lancet Oncol. 2014 15 4 415 423 10.1016/S1470‑2045(14)70063‑4 24618336
    [Google Scholar]
  12. Yetkin-Arik B. Kastelein A.W. Klaassen I. Jansen C.H.J.R. Latul Y.P. Vittori M. Biri A. Kahraman K. Griffioen A.W. Amant F. Lok C.A.R. Schlingemann R.O. van Noorden C.J.F. Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy. Biochim. Biophys. Acta Rev. Cancer 2021 1875 1 188446 10.1016/j.bbcan.2020.188446 33058997
    [Google Scholar]
  13. Tan H.W. Xu Y.M. Qin S.H. Chen G.F. Lau A.T.Y. Epigenetic regulation of angiogenesis in lung cancer. J. Cell. Physiol. 2021 236 5 3194 3206 10.1002/jcp.30104 33078404
    [Google Scholar]
  14. Li S. Anlotinib: A novel targeted drug for bone and soft tissue sarcoma. Front. Oncol. 2021 11 664853 10.3389/fonc.2021.664853 34094958
    [Google Scholar]
  15. Zhang L. Sun S. Wang Y. Mo Y. Xiong F. Zhang S. Zeng Z. Xiong W. Li G. Chen H. Guo C. Gossypol induces apoptosis of multiple myeloma cells through the JUN-JNK pathway. Am. J. Cancer Res. 2020 10 3 870 883 32266096
    [Google Scholar]
  16. Jiang X. The role of microenvironment in tumor angiogenesis. J. Exper. Clini. Canc. Res. 2020 39 1 204
    [Google Scholar]
  17. Campochiaro P.A. Akhlaq A. Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Prog. Retin. Eye Res. 2021 83 100921 10.1016/j.preteyeres.2020.100921 33248215
    [Google Scholar]
  18. Shen G. Zheng F. Ren D. Du F. Dong Q. Wang Z. Zhao F. Ahmad R. Zhao J. Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J. Hematol. Oncol. 2018 11 1 120 10.1186/s13045‑018‑0664‑7 30231931
    [Google Scholar]
  19. Bleloch J.S. Ballim R.D. Kimani S. Parkes J. Panieri E. Willmer T. Prince S. Managing sarcoma: Where have we come from and where are we going? Ther. Adv. Med. Oncol. 2017 9 10 637 659 10.1177/1758834017728927 28974986
    [Google Scholar]
  20. Sun Y. Niu W. Du F. Du C. Li S. Wang J. Li L. Wang F. Hao Y. Li C. Chi Y. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J. Hematol. Oncol. 2016 9 1 105 10.1186/s13045‑016‑0332‑8 27716285
    [Google Scholar]
  21. Meyer M. Seetharam M. First-line therapy for metastatic soft tissue sarcoma. Curr. Treat. Options Oncol. 2019 20 1 6 10.1007/s11864‑019‑0606‑9 30675651
    [Google Scholar]
  22. Abrahams C. Woudberg N.J. Lecour S. Anthracycline-induced cardiotoxicity: Targeting high-density lipoproteins to limit the damage? Lipids Health Dis. 2022 21 1 85 10.1186/s12944‑022‑01694‑y 36050733
    [Google Scholar]
  23. Tan R. Cong T. Xu G. Hao Z. Liao J. Xie Y. Lin Y. Yang X. Li Q. Liu Y. Xia Y.L. Anthracycline-induced atrial structural and electrical remodeling characterizes early cardiotoxicity and contributes to atrial conductive instability and dysfunction. Antioxid. Redox Signal. 2022 37 1-3 19 39 10.1089/ars.2021.0002 35081742
    [Google Scholar]
  24. van der Graaf W.T.A. Blay J.Y. Chawla S.P. Kim D.W. Bui-Nguyen B. Casali P.G. Schöffski P. Aglietta M. Staddon A.P. Beppu Y. Le Cesne A. Gelderblom H. Judson I.R. Araki N. Ouali M. Marreaud S. Hodge R. Dewji M.R. Coens C. Demetri G.D. Fletcher C.D. Dei Tos A.P. Hohenberger P. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012 379 9829 1879 1886 10.1016/S0140‑6736(12)60651‑5 22595799
    [Google Scholar]
  25. Mir O. Brodowicz T. Italiano A. Wallet J. Blay J.Y. Bertucci F. Chevreau C. Piperno-Neumann S. Bompas E. Salas S. Perrin C. Delcambre C. Liegl-Atzwanger B. Toulmonde M. Dumont S. Ray-Coquard I. Clisant S. Taieb S. Guillemet C. Rios M. Collard O. Bozec L. Cupissol D. Saada-Bouzid E. Lemaignan C. Eisterer W. Isambert N. Chaigneau L. Cesne A.L. Penel N. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016 17 12 1732 1742 10.1016/S1470‑2045(16)30507‑1 27751846
    [Google Scholar]
  26. Zhang R.S. Liu J. Deng Y.T. Wu X. Jiang Y. The real‐world clinical outcomes and treatment patterns of patients with unresectable locally advanced or metastatic soft tissue sarcoma treated with anlotinib in the post‐ALTER0203 trial era. Cancer Med. 2022 11 11 2271 2283 10.1002/cam4.4613 35191609
    [Google Scholar]
  27. Liu Z. Gao S. Zhu L. Wang J. Zhang P. Li P. Zhang F. Yao W. Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study. Cancer Med. 2021 10 21 7593 7600 10.1002/cam4.4286 34564939
    [Google Scholar]
  28. Colosia A. Khan S. Hackshaw M.D. Oglesby A. Kaye J.A. Skolnik J.M. A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma. Sarcoma 2016 2016 1 13 10.1155/2016/3597609 27516726
    [Google Scholar]
  29. Li J. Han B. Liu H. Outcomes of anlotinib maintenance therapy in patients with advanced NSCLC in a real-world setting. Front. Oncol. 2022 12 785865 10.3389/fonc.2022.785865 35847883
    [Google Scholar]
  30. Cai M. Zhu J. Zhou G. Efficacy and safety of treating refractory bone and soft tissue sarcoma with anlotinib in different treatment patterns. Comput. Math. Methods Med. 2022 2022 1 10 10.1155/2022/3287961 35991143
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206336884241216070930
Loading
Safety and Efficacy of Anlotinib-based Regimen in Patients with Unresectable or Metastatic Bone and Soft-tissue Sarcomas: A Retrospective Institutional Study
Bentham Science Publishers ; https://doi.org/10.2174/0118715206336884241216070930
/content/journals/acamc/10.2174/0118715206336884241216070930
/content/journals/acamc/10.2174/0118715206336884241216070930
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: anlotinib ; prognosis ; adverse events ; Bone and soft tissue sarcoma ; efficacy

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test